Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Summit Therapeutics Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.26 (market cap $1.93B), while Summit Therapeutics Inc trades at $17.29 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 7.1× Abrdn Physical Platinum Shares ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and Summit Therapeutics Inc for 16 Days on average.
| PPLT | SMMT | |
|---|---|---|
Market Cap | $1.93B | $13.71B |
Volume | 1,698,523 | 6,173,057 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $26.38 |
52-Week Low | $13.73 | $12.43 |
Typical Hold Time | 42 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.78, down 4.46% today, reflecting a bearish technical outlook with moving averages and oscillators signaling sell pressure. Recent news highlights platinum's underperformance versus other precious metals, with the term structure in contango suggesting adequate supply. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak technical signals and platinum's lag in the metals rally, though historical seasonality may offer contrarian hope. Risks include commodity price volatility and supply-demand dynamics. Investors should await updated financials for a clearer fundamental picture amid current bearish sentiment.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
